Bone metastases and tumor-induced hypercalcemia.

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Tumor-induced hypercalcemia and osteolysis result from heightened osteoclast activity and bone resorption.
• Parathyroid hormone-like protein is implicated, alongside other factors, in neoplastic bone destruction.
• Kidneys contribute to hypercalcemia in cancer patients.

Purpose of the Study:

• To review the mechanisms and treatment of tumor-induced hypercalcemia and osteolysis.
• To highlight the role of bisphosphonates in managing these oncological emergencies.

Main Methods:

• Review of existing literature on tumor-induced hypercalcemia and osteolysis.
• Analysis of bisphosphonate efficacy, particularly pamidronate, in clinical settings.
• Discussion of diagnostic challenges and emerging biomarkers for bone turnover.

Main Results:

• Pamidronate normalizes serum calcium in approximately 90% of hypercalcemic cancer patients at doses of 1.0-1.5 mg/kg.
• Bisphosphonates are potent inhibitors of osteoclast activity.
• Prolonged pamidronate use may halve osteolysis complications and provide pain relief and sclerosis in a subset of patients.

Conclusions:

• Medical therapy for tumor-induced osteolysis using non-cytotoxic agents, especially bisphosphonates, is effective.
• Further randomized trials are needed to establish optimal therapeutic regimens for bisphosphonates.
• Biochemical markers of bone turnover show promise for assessing treatment response.